Amanda Megan Cole : Citation Profile


Are you Amanda Megan Cole?

Office of Health Economics

4

H index

0

i10 index

43

Citations

RESEARCH PRODUCTION:

4

Articles

21

Papers

RESEARCH ACTIVITY:

   7 years (2014 - 2021). See details.
   Cites by year: 6
   Journals where Amanda Megan Cole has often published
   Relations with other researchers
   Recent citing documents: 2.    Total self citations: 6 (12.24 %)

MORE DETAILS IN:
ABOUT THIS REPORT:

   Permalink: http://citec.repec.org/pco941
   Updated: 2024-01-16    RAS profile: 2022-02-10    
   Missing citations? Add them    Incorrect content? Let us know

Relations with other researchers


Works with:

Cubi-Molla, Patricia (3)

Lorgelly, Paula (3)

Zamora Talaya, Bernarda (3)

Authors registered in RePEc who have co-authored more than one work in the last five years with Amanda Megan Cole.

Is cited by:

LEVAGGI, ROSELLA (2)

Viney, Rosalie (2)

Towse, Adrian (2)

Lorgelly, Paula (2)

Devlin, Nancy (2)

Pertile, Paolo (2)

Shah, Koonal (2)

Lakdawalla, Darius (1)

Goldman, Dana (1)

Garau, Martina (1)

Tsuchiya, Aki (1)

Cites to:

Towse, Adrian (7)

Shah, Koonal (6)

Devlin, Nancy (4)

Zamora Talaya, Bernarda (4)

Claxton, Karl (4)

Tsuchiya, Aki (3)

Lorgelly, Paula (2)

Hole, Arne (2)

Brazier, John (2)

Karlsberg Schaffer, Sarah (1)

McCabe, Christopher (1)

Main data


Where Amanda Megan Cole has published?


Journals with more than one article published# docs
Applied Health Economics and Health Policy2

Working Papers Series with more than one paper published# docs
Briefing / Office of Health Economics4

Recent works citing Amanda Megan Cole (2024 and 2023)


YearTitle of citing document
2023Open and inclusive: fair processes for financing universal health coverage. (2023). Kurowski, Christoph. In: LSE Research Online Documents on Economics. RePEc:ehl:lserod:119795.

Full description at Econpapers || Download paper

202310 Years of AMNOG: What is the Willingness-to-Pay for Pharmaceuticals in Germany?. (2023). Stargardt, Tom ; Bussgen, Melanie. In: Applied Health Economics and Health Policy. RePEc:spr:aphecp:v:21:y:2023:i:5:d:10.1007_s40258-023-00815-7.

Full description at Econpapers || Download paper

Works by Amanda Megan Cole:


YearTitleTypeCited
2016How Can Health Technology Assessments in the Asia-Pacific Area Respond to Increased Clinical Uncertainty as a Consequence of Expedited US and EU Regulatory Processes? In: Briefing.
[Full Text][Citation analysis]
paper0
2016“New Age” Decision Making in HTA: Is It Applicable in Asia? In: Briefing.
[Full Text][Citation analysis]
paper0
2019Indication-Based Pricing (IBP) Discussion Paper: Should drug prices differ by indication? In: Briefing.
[Full Text][Citation analysis]
paper0
2019Documento de debate sobre la fijación de precios en función de la indicación (IBP) ¿Deben variar los precios de los medicamentos según la indicación? In: Briefing.
[Full Text][Citation analysis]
paper0
2015Do Respondents Completing Abstract, Hypothetical Priority-setting Exercises Agree With the Policy Implications of Their Choices? In: Consulting Report.
[Full Text][Citation analysis]
paper3
2015Assessing the Use of Multi-indication Medicines: A Review of Current Data Capabilities in the UK In: Consulting Report.
[Full Text][Citation analysis]
paper1
2015Data Governance Arrangements for Real-World Evidence In: Consulting Report.
[Full Text][Citation analysis]
paper1
2016Improving Efficiency and Resource Allocation in Future Cancer Care In: Consulting Report.
[Full Text][Citation analysis]
paper0
2017Data Governance Arrangements for Real-World Evidence: South Korea In: Consulting Report.
[Full Text][Citation analysis]
paper0
2018Barriers to Uptake of Minimal Access Surgery in the United Kingdom In: Consulting Report.
[Full Text][Citation analysis]
paper2
2018The Debate on Indication-Based Pricing in the U.S. and Five Major European Countries In: Consulting Report.
[Full Text][Citation analysis]
paper5
2018Legal Barriers to the Better Use of Health Data to Deliver Pharmaceutical Innovation In: Consulting Report.
[Full Text][Citation analysis]
paper1
2020Indication-Based Pricing (IBP) Consultation Report In: Consulting Report.
[Full Text][Citation analysis]
paper2
2020NICE ‘Optimised’ Decisions: What is the Recommended Level of Patient Access? In: Consulting Report.
[Full Text][Citation analysis]
paper0
2021Payment Models for Multi-Indication Therapies In: Consulting Report.
[Full Text][Citation analysis]
paper0
2016A Review of NICE Methods Across Health Technology Assessment Programmes: Differences, Justifications and Implications In: Research Paper.
[Full Text][Citation analysis]
paper4
2016An Analysis of NICE Technology Appraisal Decisions ‘Recommended in Line with Clinical Practice’ In: Research Paper.
[Full Text][Citation analysis]
paper0
2018Economics of Innovative Payment Models Compared with Single Pricing of Pharmaceuticals In: Research Paper.
[Full Text][Citation analysis]
paper7
2019Making Outcome-Based Payment a Reality in the NHS In: Research Paper.
[Full Text][Citation analysis]
paper6
2019Value, Access, and Incentives for Innovation: Policy Perspectives on Alternative Models for Pharmaceutical Rebates In: Research Paper.
[Full Text][Citation analysis]
paper0
2021Making Outcome-Based Payment a Reality in the NHS. Phase Two: Practical Considerations In: Research Paper.
[Full Text][Citation analysis]
paper0
2014Are the UK Systems of Innovation and Evaluation of Medical Devices Compatible? The Role of NICE’s Medical Technologies Evaluation Programme (MTEP) In: Applied Health Economics and Health Policy.
[Full Text][Citation analysis]
article2
2017A Review of NICE Methods and Processes Across Health Technology Assessment Programmes: Why the Differences and What is the Impact? In: Applied Health Economics and Health Policy.
[Full Text][Citation analysis]
article4
2018Valuing EQ-5D-5L health states ‘in context’ using a discrete choice experiment In: The European Journal of Health Economics.
[Full Text][Citation analysis]
article4
2020Outcome-Based Payment Schemes: What Outcomes Do Patients with Cancer Value? In: The Patient: Patient-Centered Outcomes Research.
[Full Text][Citation analysis]
article1

CitEc is a RePEc service, providing citation data for Economics since 2001. Sponsored by INOMICS. Last updated December, 10 2023. Contact: CitEc Team